#BEGIN_DRUGCARD DB04455

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
41139

# Chemical_Formula:
C5H12NO2

# Chemical_IUPAC_Name:
(carboxymethyl)trimethylazanium

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A naturally occurring compound that has been of interest for its role in osmoregulation. As a drug, betaine hydrochloride has been used as a source of hydrochloric acid in the treatment of hypochlorhydria. Betaine has also been used in the treatment of liver disorders, for hyperkalemia, for homocystinuria, and for gastrointestinal disturbances. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1341)

# Dosage_Forms:
Not Available

# Drug_Category:
Gastrointestinal Agents
Lipotropic Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Trimethyl Glycine

# HET_ID:
BET

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C5H11NO2/c1-6(2,3)4-5(7)8/h4H2,1-3H3/p+1

# InChI_Key:
InChIKey=KWIUHFFTVRNATP-UHFFFAOYSA-O

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
4455

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
118.1543

# Molecular_Weight_Mono:
118.086803633

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1WWJ

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-2.1

# Predicted_LogS:
-1.9

# Predicted_Water_Solubility:
1.75e+00 g/l

# Primary_Accession_No:
DB04455

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
248

# PubChem_Substance_ID:
46506049

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT00674

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
C[N+](C)(C)CC(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:23:21 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Periplasm

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
M24856

# Drug_Target_1_GenBank_ID_Protein:
147373

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
proX

# Drug_Target_1_Gene_Sequence:
>993 bp
ATGCGACATAGCGTACTTTTTGCGACAGCGTTTGCCACGCTTATCTCTACACAAACTTTT
GCTGCCGATCTGCCGGGCAAAGGCATTACTGTTAATCCAGTTCAGAGCACCATCACTGAA
GAAACCTTCCAGACGCTGCTGGTCAGTCGTGCGCTGGAGAAATTAGGTTATACCGTCAAC
AAACCCAGCGAAGTAGATTACAACGTTGGCTACACCTCGCTTGCTTCCGGCGATGCAACC
TTCACCGCCGTGAACTGGACGCCACTGCATGACAACATGTACGAAGCTGCCGGTGGCGAT
AAGAAATTTTATCGTGAAGGGGTATTTGTTAACGGCGCGGCACAGGGTTACCTGATCGAT
AAGAAAACCGCCGACCAGTACAAAATCACCAACATCGCACAACTGAAAGATCCGAAGATC
GCCAAACTGTTCGATACCAACGGCGACGGAAAAGCGGATTTAACCGGTTGTAACCCTGGC
TGGGGCTGCGAAGGTGCGATCAACCACCAGCTTGCCGCGTATGAACTGACCAACACCGTG
ACGCATAATCAGGGGAACTACGCAGCGATGATGGCCGACACCATCAGTCGCTACAAAGAG
GGCAAACCGGTGTTTTATTACACCTGGACGCCGTACTGGGTGAGTAACGAACTGAAGCCG
GGCAAAGATGTCGTCTGGTTGCAGGTGCCGTTCTCCGCACTGCCGGGCGATAAAAACGCC
GATACCAAACTGCCGAATGGTGCGAATTATGGCTTCCCGGTCAGCACCATGCATATCGTT
GCCAACAAAGCCTGGGCCGAGAAAAACCCGGCAGCAGCGAAACTGTTTGCCATTATGCAG
TTGCCAGTGGCAGATATTAACGCCCAGAACGCCATTATGCATGACGGCAAAGCCTCAGAA
GGCGATATTCAGGGACACGTTGATGGTTGGATCAAAGCCCACCAGCAGCAGTTCGATGGC
TGGGTGAATGAGGCGCTGGCAGCGCAGAAGTAA

# Drug_Target_1_General_Function:
Amino acid transport and metabolism

# Drug_Target_1_General_References:
2649479	Gowrishankar J: Nucleotide sequence of the osmoregulatory proU operon of Escherichia coli. J Bacteriol. 1989 Apr;171(4):1923-31.
3305496	Barron A, Jung JU, Villarejo M: Purification and characterization of a glycine betaine binding protein from Escherichia coli. J Biol Chem. 1987 Aug 25;262(24):11841-6.
9205837	Yamamoto Y, Aiba H, Baba T, Hayashi K, Inada T, Isono K, Itoh T, Kimura S, Kitagawa M, Makino K, Miki T, Mitsuhashi N, Mizobuchi K, Mori H, Nakade S, Nakamura Y, Nashimoto H, Oshima T, Oyama S, Saito N, Sampei G, Satoh Y, Sivasundaram S, Tagami H, Horiuchi T, et al.: Construction of a contiguous 874-kb sequence of the Escherichia coli -K12 genome corresponding to 50.0-68.8 min on the linkage map and analysis of its sequence features. DNA Res. 1997 Apr 28;4(2):91-113.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
3717

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
36023

# Drug_Target_1_Name:
Glycine betaine-binding periplasmic protein precursor

# Drug_Target_1_Number_of_Residues:
330

# Drug_Target_1_PDB_ID:
1R9Q

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF04069	OpuAC

# Drug_Target_1_Protein_Sequence:
>Glycine betaine-binding periplasmic protein precursor
MRHSVLFATAFATLISTQTFAADLPGKGITVNPVQSTITEETFQTLLVSRALEKLGYTVN
KPSEVDYNVGYTSLASGDATFTAVNWTPLHDNMYEAAGGDKKFYREGVFVNGAAQGYLID
KKTADQYKITNIAQLKDPKIAKLFDTNGDGKADLTGCNPGWGCEGAINHQLAAYELTNTV
THNQGNYAAMMADTISRYKEGKPVFYYTWTPYWVSNELKPGKDVVWLQVPFSALPGDKNA
DTKLPNGANYGFPVSTMHIVANKAWAEKNPAAAKLFAIMQLPVADINAQNAIMHDGKASE
GDIQGHVDGWIKAHQQQFDGWVNEALAAQK

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-21

# Drug_Target_1_Specific_Function:
Member of a multicomponent binding-protein-dependent transport system (the proU transporter) which serves as the glycine betaine/L-proline transporter

# Drug_Target_1_SwissProt_ID:
P0AFM2

# Drug_Target_1_SwissProt_Name:
PROX_ECOLI

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
6.31

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
BA000022

# Drug_Target_2_GenBank_ID_Protein:
1653851

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
kaiB

# Drug_Target_2_Gene_Sequence:
>318 bp
ATGAGCCCCTTTAAAAAAACTTACGTTCTCAAACTCTACGTAGCTGGCAACACCCCCAAC
TCTGTGCGGGCCTTAAAAATGCTAAAAAATATCCTTGAGCAAGAATTCCAGGGAGTTTAT
GCCCTCAAAGTAATCGACGTGTTGAAAAATCCCCAATTAGCCGAAGAAGATAAAATTCTT
GCCACCCCCACCTTGGCTAAAATCCTACCGCCCCCTGTCAGGAAAATCATCGGCGACCTT
TCCGACCGAGAGAAAGTATTGATTGGTTTAGACCTGCTCTATGACGAAATTCGGGAACGG
GAAGCAGAAGACCAATAG

# Drug_Target_2_General_Function:
Posttranslational modification, protein turnover, chaperones

# Drug_Target_2_General_References:
8905231	Kaneko T, Sato S, Kotani H, Tanaka A, Asamizu E, Nakamura Y, Miyajima N, Hirosawa M, Sugiura M, Sasamoto S, Kimura T, Hosouchi T, Matsuno A, Muraki A, Nakazaki N, Naruo K, Okumura S, Shimpo S, Takeuchi C, Wada T, Watanabe A, Yamada M, Yasuda M, Tabata S: Sequence analysis of the genome of the unicellular cyanobacterium Synechocystis sp. strain PCC6803. II. Sequence determination of the entire genome and assignment of potential protein-coding regions. DNA Res. 1996 Jun 30;3(3):109-36.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
2891

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
11935

# Drug_Target_2_Name:
Circadian clock protein kaiB

# Drug_Target_2_Number_of_Residues:
105

# Drug_Target_2_PDB_ID:
1WWJ

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF07689	KaiB

# Drug_Target_2_Protein_Sequence:
>Circadian clock protein kaiB
MSPFKKTYVLKLYVAGNTPNSVRALKMLKNILEQEFQGVYALKVIDVLKNPQLAEEDKIL
ATPTLAKILPPPVRKIIGDLSDREKVLIGLDLLYDEIREREAEDQ

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Component of the kaiABC clock protein complex, which constitutes the main circadian regulator in cyanobacteria. The kaiABC complex may act as a promoter-nonspecific transcription regulator that represses transcription, possibly by acting on the state of chromosome compaction. In the complex, it decreases the phosphorylation status of kaiC. It has no effect on kaiC by itself, but instead needs the presence of both kaiA and kaiC, suggesting that it acts by antagonizing the interaction between kaiA and kaiC

# Drug_Target_2_SwissProt_ID:
P74645

# Drug_Target_2_SwissProt_Name:
KAIB_SYNY3

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
6.84

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB04455
